KEAP1通过抑制NSCLC中的PD-L1表达来促进抗瘤免疫力
Jinghan Li1,2, Daiwang Shi1,2,3, Siyi Li1,2
1Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, China.
凯普1 (凯尔奇类ECH关联蛋白1) 准PD-L1 (编程死亡配体1) 降解,增强抗癌免疫力. 将Keap1与PD-L1免疫疗法结合,在非小细胞肺癌中显示出协同效应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 免疫疗法是癌症的关键治疗方法,PD-L1 (编程死亡连接体1) 是非小细胞肺癌 (NSCLC) 的目标.
- 在肺癌中PD-L1的调节机制和功能仍然不完全理解.
- 了解PD-L1调节对于改善抗癌免疫反应至关重要.
研究的目的:
- 阐明在NSCLC中PD-L1降解的调节机制.
- 研究KEAP1 (凯尔奇类ECH相关蛋白1) 在PD-L1调节和抗癌免疫中的作用.
- 评估针对NSCLC中KEAP1-PD-L1途径的治疗潜力.
主要方法:
- 研究KEAP1作为PD-L1无化和降解的E3酶.
- 在体内评估KEAP1过度表达对瘤生长和细胞毒性T细胞激活的影响.
- 分析了KEAP1表达升高和抗PD-L1免疫疗法的综合效应.
- 与NSCLC患者预后相关的KEAP1和PD-L1表达水平.
主要成果:
- KEAP1作为E3结合酶起作用,促进PD-L1的无化和随后的降解.
- 过度表达KEAP1抑制了瘤生长,并在体内增强了细胞毒性T细胞激活.
- 联合KEAP1升高和抗PD-L1治疗显示出协同作用的抗瘤效应.
- KEAP1和PD-L1表达水平与NSCLC预后有显著的关联.
结论:
- KEAP1在调节PD-L1稳定性方面发挥着关键作用,从而影响NSCLC的抗癌免疫力.
- KEAP1-PD-L1信号通路是NSCLC免疫逃生的一个关键机制.
- KEAP1激动剂代表了一种有前途的治疗策略,可以增强抗瘤免疫力,并提高NSCLC免疫疗法的疗效.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10:11Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
相关概念视频
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
